{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:50:34Z","timestamp":1767135034054,"version":"build-2238731810"},"publisher-location":"Chichester, UK","reference-count":178,"publisher":"John Wiley & Sons, Ltd","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.1002\/14651858.cd006625.pub2","type":"reference-entry","created":{"date-parts":[[2010,1,18]],"date-time":"2010-01-18T14:47:59Z","timestamp":1263826079000},"source":"Crossref","is-referenced-by-count":17,"title":["Quetiapine versus other atypical antipsychotics for schizophrenia"],"prefix":"10.1002","author":[{"given":"Katja","family":"Komossa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Rummel-Kluge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franziska","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Hunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Schwarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manit","family":"Srisurapanont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Werner","family":"Kissling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,1,20]]},"reference":[{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB1|cit1","doi-asserted-by":"crossref","first-page":"598","DOI":"10.4088\/JCP.v64n0516","article-title":"Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics","volume":"64","author":"Atmaca","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB2|cit2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/01.wnf.0000172993.89879.0f","article-title":"Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapiy-refractory schizophrenia","volume":"28","author":"Conley","year":"2005","journal-title":"Clinical Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB3|cit3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.psyneuen.2005.08.010","article-title":"A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia","volume":"31","author":"Kelly","year":"2006","journal-title":"Psychoneuroendocrinology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB4|cit4","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4088\/JCP.v66n0111","article-title":"Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine","volume":"66","author":"Kelly","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB5|cit5","first-page":"501","article-title":"Risperidone vs quetiapine vs fluphenazine in treatment - resistant schizophrenia: neuropsychological outcome","volume":"31","author":"Richardson","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB6|cit6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/01.jcp.0000204137.82298.06","article-title":"A 24-week randomized study of olanzapine versus ziprasidone in the treatment of schizophrenia or schizoaffective disorder in patients with prominent depressive symptoms","volume":"26","author":"Kinon","year":"2006","journal-title":"Journal of Clinical Psychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB7|cit7","first-page":"262","article-title":"A double blind comparing study between the effects of quetiapine and clozapine on the life quality of the patients with schizophrenia","volume":"17","author":"Li","year":"2005","journal-title":"Medical Journal of Chinese Peoples Health"},{"key":"10.1002\/14651858.CD006625.pub2-BIB8|cit8","first-page":"219","article-title":"A study of quetiapine and clozapine in treatment of first-episode schizophrenia","volume":"28","author":"Li","year":"2002","journal-title":"Chinese Journal of Nerv-and Mental Disease"},{"key":"10.1002\/14651858.CD006625.pub2-BIB9|cit9","first-page":"306","article-title":"A study of quetiapine and clozapine in treatment of schizophrenia","volume":"29","author":"Li","year":"2003","journal-title":"Chinese Journal of Nerv-and Mental Disease"},{"issue":"12","key":"10.1002\/14651858.CD006625.pub2-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB11|cit11","first-page":"6","article-title":"A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms","volume":"17","author":"Liu","year":"2004","journal-title":"Shandong Archires of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB12|cit12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1176\/ajp.2006.163.4.600","article-title":"Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment","volume":"163","author":"McEvoy","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB13|cit13","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"The effects of olanzapine, quetiapine and risperidone on neurocognitive function in first-episode psychosis: a double-blind 52-week comparison","author":"Keefe","year":"2006"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006625.pub2-BIB14|cit14","first-page":"S525","article-title":"Comparison of atypicals in first-episode psychosis: a randomized, 52-week comparison of olanzapine, quetiapine, and risperidone","volume":"15","author":"Lieberman","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB17|cit15","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"Comparison of clozapine versus other atypical drugs in prospectively defined, unresponsive patients","author":"McEvoy","year":"2006"},{"key":"10.1002\/14651858.CD006625.pub2-BIB15|cit16","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1176\/ajp.2007.164.7.1050","article-title":"Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: A randomized, double-blind 52-week comparison","volume":"164","author":"McEvoy","year":"2007","journal-title":"American Journal of Psychiatry"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD006625.pub2-BIB16|cit17","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/S0920-9964(06)70390-5","article-title":"Clinical effectiveness and predictors of treatment non-adherence: comparison of olanzapine, quetiapine, and risperidone in first-episode psychosis","volume":"86","author":"McEvoy","year":"2006","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB18|cit18","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.pnpbp.2004.01.019","article-title":"Effect of switching to atypical antipsychotics on memory in patients with chronic schizophrenia","volume":"28","author":"Mori","year":"2004","journal-title":"Progress in Neuro-Psychopharmacology and Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB19|cit19","first-page":"190","article-title":"The metabolic and clinical effects of olanzapine and quetiapine: preliminary findings from a randomized single-blind trial in patients with schizophrenia","volume":"67","author":"Ozguven","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"45","key":"10.1002\/14651858.CD006625.pub2-BIB20|cit20","first-page":"1","article-title":"Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial","volume":"6","author":"Gharabawi","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006625.pub2-BIB21|cit21","first-page":"S503","article-title":"Risperidone vs quetiapine in inpatients with schizophrenia: a double-blind placebo-controlled study","volume":"15","author":"Greenspan","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1-3","key":"10.1002\/14651858.CD006625.pub2-BIB22|cit22","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.schres.2006.03.027","article-title":"A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalization","volume":"85","author":"Potkin","year":"2006","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006625.pub2-BIB23|cit23","first-page":"501","article-title":"A placebo - controlled study of risperidone vs quetiapine for symptom response and readiness for discharge among agitated inpatients with schizophrenia","volume":"31","author":"Potkin","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB24|cit24","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","article-title":"Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms","volume":"255","author":"Riedel","year":"2005","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"key":"10.1002\/14651858.CD006625.pub2-BIB25|cit25","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00406-007-0739-x","article-title":"Efficacy of olanzapine versus quetiapine on cognitive dysfunctions with an acute episode of schizophrenia","volume":"748","author":"Riedel","year":"2007","journal-title":"European Archieves of Psychiatry and Clinical Neuroscience"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB26|cit26","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1007\/s00406-005-0622-6","article-title":"Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms","volume":"255","author":"Riedel","year":"2005","journal-title":"European Archives of Psychiatry and Clinical Neuroscience"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB27|cit27","first-page":"150","article-title":"Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study","volume":"67","author":"Sacchetti","year":"2004","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006625.pub2-BIB31|cit28","series-title":"Proceedings of the Thematic Conference of the World Psychiatric Association on \"Treatments in Psychiatry: An Update\"; 2004 Nov 10-13; Florence, Italy","article-title":"Comparison of quetiapine, olanzapine and risperidone in a randomized study in patients with schizophrenia","author":"Sacchetti","year":"2004"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006625.pub2-BIB30|cit29","doi-asserted-by":"crossref","first-page":"S286","DOI":"10.1016\/S0924-977X(04)80342-0","article-title":"Comparison of quetiapine, olanzapine, and risperidone in schizophrenia","volume":"14","author":"Sacchetti","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB29|cit30","doi-asserted-by":"crossref","first-page":"S350","DOI":"10.1016\/S0924-977X(03)92114-6","article-title":"Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study","volume":"13","author":"Sacchetti","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB28|cit31","series-title":"Proceedings of the 16th European College of Neuropsychopharmacology Congress; 2003 Sep 20-24; Prague, Czech Republic","article-title":"Comparison of quetiapine, olanzapine and risperidone in patients with schizophrenia: interim results of a randomised, rater-blinded study","author":"Sacchetti","year":"2003"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB32|cit32","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/hup.763","article-title":"Quetiapine versus olanzapine for the treatment of negative symptoms in patients with schizophrenia","volume":"21","author":"Sirota","year":"2006","journal-title":"Human Psychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB33|cit33","first-page":"170","article-title":"The effectiveness of quetiapine versus olanzapine in improving negative symptoms of patients with schizophrenia","volume":"67","author":"Sirota","year":"2004","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB34|cit34","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/ajp.2006.163.4.611","article-title":"Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic","volume":"163","author":"Stroup","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB35|cit35","doi-asserted-by":"crossref","first-page":"S291","DOI":"10.1016\/S0924-977X(03)91983-3","article-title":"A double-blind comparison of olanzapine and quetiapine in treatment of acute exacerbations of schizophrenic or schizoaffective disorders","volume":"13","author":"Svestka","year":"2003","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB36|cit36","doi-asserted-by":"crossref","unstructured":"Voruganti LP Awad AG Parker G Forrest C Usmani Y Fernando MLD Senthilal S Cognition, functioning and quality of life in schizophrenia treatment: Results of a one-year randomized controlled trial of olanzapine and quetiapine Schizophrenia Research 2007 146 55","DOI":"10.1016\/j.schres.2007.08.002"},{"issue":"11","key":"10.1002\/14651858.CD006625.pub2-BIB37|cit37","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1176\/ajp.2006.163.11.1918","article-title":"Improvement in social competence with short-term atypical antipsychotic treatment: a randomized, double-blind comparison of quetiapine versus risperidone for social competence, social cognition, and neuropsychological functioning","volume":"163","author":"Harvey","year":"2006","journal-title":"American Journal of Psychiatry"},{"issue":"7","key":"10.1002\/14651858.CD006625.pub2-BIB38|cit38","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4088\/JCP.v67n0712","article-title":"Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study","volume":"67","author":"Zhong","year":"2006","journal-title":"Journal of Clinical Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB39|cit39","first-page":"152","article-title":"A comparative study between quetiapine and clozapine in the treatment of schizophrenia and the relation with the plasman levels of IL-2, SIL-2R","volume":"16","author":"An","year":"2003","journal-title":"Schuan Mental Health"},{"key":"10.1002\/14651858.CD006625.pub2-BIB40|cit40","first-page":"474","article-title":"Superior cognitive efficacy of atypical antipsychotics olanzapine, risperidone, and quetiapine, as a group, relative to low doses of conventional antipsychotics","volume":"31","author":"Antonova","year":"2005","journal-title":"Schizophrenia Bulletin"},{"issue":"8","key":"10.1002\/14651858.CD006625.pub2-BIB41|cit41","first-page":"1","article-title":"Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia","volume":"6","author":"Ascher-Svanum","year":"2006","journal-title":"BMC Psychiatry"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB42|cit42","first-page":"S403","article-title":"Side effects of atypical antipsychotics - prediction factor for compliance","volume":"16","author":"Baloescu","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB43|cit43","series-title":"Proceedings of the XIII World Congress of Psychiatry; 2005 Sept 10-15th; Cairo, Egypt","article-title":"Naturalistic study of aripiprazole treatment","author":"Beuzen","year":"2005"},{"key":"10.1002\/14651858.CD006625.pub2-BIB44|cit44","unstructured":"Byerly M Weber M Clozapine versus quetiapine for schizophrenia Stanley Foundation Research Programs 1999"},{"key":"10.1002\/14651858.CD006625.pub2-BIB45|cit45","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"A randomized, double-blind pilot trial of switching to quetiapine vs. risperidone continuation in outpatients with risperidone-associated sexual dysfunction","author":"Byerly","year":"2006"},{"key":"10.1002\/14651858.CD006625.pub2-BIB46|cit46","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada","article-title":"Quetiapine and risperidone in the treatment of schizophrenia: a short- and long-term, non-randomized study","author":"Canas","year":"2006"},{"issue":"36","key":"10.1002\/14651858.CD006625.pub2-BIB47|cit47","first-page":"63","article-title":"Characteristics of the sexual disturbance caused by chlorpromazine, risperidone, quetiapine and olanzapine and their associations with the changes of blood glucose and blood lipids in male patients with schizophrenia","volume":"9","author":"Cao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"20","key":"10.1002\/14651858.CD006625.pub2-BIB48|cit48","first-page":"148","article-title":"Comparison of the effects of chlorpromazine, risperidone and quetiapine on hypothalamic-pituitary-gonadal axis and sexual function in male patients with schizophrenia","volume":"9","author":"Cao","year":"2005","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB49|cit49","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/S0924-977X(06)70201-2","article-title":"Comparison of risperidone, olanzapine and quetiapine in relation to body weight, serum blood glucose and prolactin levels","volume":"16","author":"Chaudhry","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB50|cit50","first-page":"291","article-title":"Comparative study on the effect of olanzapine and seroquel of schizophrenia","volume":"13","author":"Dai","year":"2004","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"8","key":"10.1002\/14651858.CD006625.pub2-BIB51|cit51","first-page":"712","article-title":"Comparison of efficacy and safety of aripiprazole and quetiapine in the treatment of schizophrenia","volume":"14","author":"Dai","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Sience"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB52|cit52","first-page":"76","article-title":"A comparative study of risperidone and quetiapine in the treatment of schizophrenia and relationship between efficacy and the serum levels of il-2?sil-2r","volume":"17","author":"Ding","year":"2004","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB53|cit53","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.4088\/JCP.v66n0810","article-title":"Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of theiIntercontinental schizophrenia outpatient health outcomes (IC-SOHO) study","volume":"66","author":"Dossenbach","year":"2005","journal-title":"Journal of Clinical Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB54|cit54","first-page":"511","article-title":"A study of quetiapine and clozapine in treatment of chronic schizophrenia","volume":"26","author":"Feng","year":"2003","journal-title":"Journal of Luzhou Medical College"},{"key":"10.1002\/14651858.CD006625.pub2-BIB55|cit55","first-page":"1","article-title":"Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial.","volume":"1","author":"Emsley","year":"2005","journal-title":"International Journal of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB56|cit56","first-page":"178","article-title":"A study of quetiapine in treatment of negative symptoms dominant schizophrenia","volume":"18","author":"Fan","year":"2005","journal-title":"Sichuai Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD006625.pub2-BIB57|cit57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.schres.2005.06.004","article-title":"The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial","volume":"78","author":"Fleischhacker","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB58|cit58","first-page":"313","article-title":"A comparative study of quetiapine vs clozapine in the treatment of schizophrenia","volume":"11","author":"Fu","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB59|cit59","first-page":"221","article-title":"A study of quetiapine in the treatment of first-onset schizophrenia","volume":"13","author":"Gao","year":"2003","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB60|cit60","doi-asserted-by":"crossref","first-page":"S378","DOI":"10.1016\/S0924-977X(06)70455-2","article-title":"Sexual side effects of antipsychoticcs and treatment adherence","volume":"16","author":"Garc\u00eda","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB61|cit61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/01.jcp.0000104913.75206.62","article-title":"A randomized evaluation of the effects of six antipsychotic agents on QTC, in the absence and presence of metabolic inhibition","volume":"24","author":"Harrigan","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB62|cit62","first-page":"335","article-title":"A controlled study on quetiapine and clozapine in the treatment of schizophrenic patients","volume":"15","author":"He","year":"2003","journal-title":"Medical Journal of Chinese Civil Administration"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB63|cit63","first-page":"206","article-title":"Effectiveness of quetiatine vs clozapine in the treatment of schizophrenia","volume":"9","author":"Huang","year":"2003","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB64|cit64","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1600-0447.2003.00251.x","article-title":"Psychotic disorders and gonadal function: Evidence supporting the oestrogen hypothesis","volume":"109","author":"Huber","year":"2004","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006625.pub2-BIB65|cit65","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00213-002-1052-z","article-title":"Subjective well-being and quality of life under atypical antipsychotic treatment","volume":"162","author":"A.","year":"2002","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB66|cit66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13651500600579068","article-title":"Clinical experience with atypical antipsychotics in acute inpatient unit: Focus on quetiapine","volume":"10","author":"Keks","year":"2006","journal-title":"International Journal of Psychiatry in Clinical Practice"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB67|cit67","doi-asserted-by":"crossref","first-page":"S430","DOI":"10.1016\/S0924-977X(06)70549-1","article-title":"Do second-generation antipsychotics disrupt decision-making abilities in schizophrenia?","volume":"16","author":"Kelemen","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006625.pub2-BIB68|cit68","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.1016\/S0924-977X(04)80250-5","article-title":"The comparison of risperidone, olanzapine and quetiapine in the treatment of chronic schizophrenia and schizoaffective disorder","volume":"14","author":"Kim","year":"2004","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB69|cit69","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/01.jcp.0000106220.36344.04","article-title":"A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning","volume":"24","author":"Knegtering","year":"2004","journal-title":"Journal of Clinical Psychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB70|cit70","first-page":"260","article-title":"Quetiapine in treatment of schizophrenia: a randomized, controlled, multicentre study","volume":"20","author":"Li","year":"2001","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB71|cit71","first-page":"267","article-title":"A comparative study between quetiapine and clozapine in the treatment of schizophrenia.","volume":"12","author":"Li","year":"2002","journal-title":"Jiuheyuan Hospital of Shishou"},{"issue":"12","key":"10.1002\/14651858.CD006625.pub2-BIB72|cit72","first-page":"718, 721","article-title":"A comparison of cognitive function in the first-onset schizophrenia treated with quetiapine and clozapine","volume":"15","author":"Li","year":"2003","journal-title":"Medical Journal of Chinese People Health"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB73|cit73","first-page":"45","article-title":"Comparison of efficacy and safety of seroquel and resperidone in the treatment of schizophrenia","volume":"12","author":"Li","year":"2003","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"11","key":"10.1002\/14651858.CD006625.pub2-BIB74|cit74","first-page":"1007-8, 36","article-title":"A comparison analysis on the efficacy of quetiapine and risperidone in cognitive function of schizophrenia","volume":"14","author":"Li","year":"2005","journal-title":"Chinese Journal of Behavioral Medical Science"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB75|cit75","first-page":"6","article-title":"A controlled study of quetiapine and clozapine in the treatment of schizophrenia with predominantly negative symptoms","volume":"17","author":"Liu","year":"2004","journal-title":"Shandong Archires of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB76|cit76","first-page":"748","article-title":"A study of quetiapine with small doze of clozapine in treatment of resistant schizophrenia","volume":"17","author":"Liu","year":"2005","journal-title":"Medical Journal of Chinese People\u00b4s Health"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB77|cit77","first-page":"57","article-title":"Comparative study on the psychopathology and the quality of life of schizophrenia treated with risperidone, clozapine and quetiapine","volume":"20","author":"Lu","year":"2005","journal-title":"Journal of Nursing Science"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB78|cit78","first-page":"269","article-title":"The comparative study of quetiapine and clozapine in the treatment of female schizophrene","volume":"17","author":"Luo","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"9","key":"10.1002\/14651858.CD006625.pub2-BIB79|cit79","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1185\/030079904X2312","article-title":"A comparison of extrapyramidal symptoms in older outpatients treated with quetiapine or risperidone","volume":"20","author":"Mintzer","year":"2004","journal-title":"Current Medical Research and Opinion"},{"issue":"11","key":"10.1002\/14651858.CD006625.pub2-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0149-2918(00)89080-3","article-title":"A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study","volume":"23","author":"Mullen","year":"2001","journal-title":"Clinical Therapeutics"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB81|cit81","doi-asserted-by":"crossref","first-page":"S415","DOI":"10.1016\/S0924-977X(06)70522-3","article-title":"SNAP-25 gene polymorphisms and weight gain in schizophrenic patients treated with atypical antipsychotics","volume":"16","author":"Musil","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB82|cit82","first-page":"244","article-title":"A controlled study of domestic quetiapine and risperidone in the treatment of first-episode schizophrenia","volume":"10","author":"Pan","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"10","key":"10.1002\/14651858.CD006625.pub2-BIB83|cit83","first-page":"597-598, 637","article-title":"A comparative study of domestic quetiapine and risperidone in the treatment of schizophrenia","volume":"16","author":"Pan","year":"2004","journal-title":"Medical Journal of Chinese Peoples Health"},{"key":"10.1002\/14651858.CD006625.pub2-BIB84|cit84","first-page":"403","article-title":"Influence of three antipsychotic drugs on electrocardiogram in patients with schizophrenia","volume":"21","author":"Pan","year":"2004","journal-title":"Journal of XinXiang Medical College"},{"issue":"7","key":"10.1002\/14651858.CD006625.pub2-BIB85|cit85","first-page":"1007","article-title":"Effect of quetiapine fumarate and clozapine on clinical rehabilitation of schizophrenia:a controlled study","volume":"6","author":"Pang","year":"2002","journal-title":"Chinese Journal of Clinical Rehabilitation"},{"issue":"12","key":"10.1002\/14651858.CD006625.pub2-BIB86|cit86","first-page":"1557","article-title":"Control study of quetiapine on schizophrenia mainly with negative symptoms","volume":"13","author":"Peng","year":"2004","journal-title":"Modern Journal of Integrated Traditional Chinese and Western Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB87|cit87","first-page":"78-79, 119","article-title":"Comparison of efficacy and safety of quetiapine and risperidone in the treatment of schizophrenia","volume":"16","author":"Qi","year":"2004","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB88|cit88","first-page":"110","article-title":"Cost-effectiveness analysis of 3 kinds of therapeutic schemes for schizophrenia","volume":"4","author":"Qian","year":"2004","journal-title":"Evaluation and Analysis of Drug-use in Hospital of China"},{"key":"10.1002\/14651858.CD006625.pub2-BIB89|cit89","series-title":"Proceedings of the XXIV Collegium Internationale Neuro-Psychopharmacologicum; 2004 June 20-24; Paris, France","first-page":"1","article-title":"Quetiapine (\"Seroquel\") and olanzapine for acute treatment of patients with schizophrenia: an open-label, comparative study","author":"Reznik","year":"2004"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD006625.pub2-BIB90|cit90","doi-asserted-by":"crossref","first-page":"S419","DOI":"10.1016\/S0924-977X(06)70530-2","article-title":"Association of leptin gene polymorphism with antipsychotic drug-induced weight gain","volume":"16","author":"Ryu","year":"2006","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB91|cit91","series-title":"Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA","article-title":"Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychotic disorders","author":"Sajatovic","year":"2002"},{"key":"10.1002\/14651858.CD006625.pub2-BIB92|cit92","series-title":"Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25, Toronto, Canada","article-title":"Effectiveness of atypical antipsychotics for substance abuse in schizophrenia patients","author":"Swanson","year":"2006"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB93|cit93","first-page":"27","article-title":"A controlled study of schizophrenia treated with quetiapine and clozapine","volume":"15","author":"Tang","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB94|cit94","first-page":"167","article-title":"A comparative study of quetiapine and clozapine in the treatment of recurrent schizophrenia","volume":"18","author":"Tang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB95|cit95","first-page":"200","article-title":"A controlled study on seroquel and risperidone in the treatment of schizophrenic patients","volume":"10","author":"Wang","year":"2000","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB96|cit96","first-page":"167","article-title":"Comparative study of effects of quetiapine and clozapine on quality of life of schizophrenics","volume":"10","author":"Wang","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB97|cit97","first-page":"551","article-title":"Comparation of quetiapine and clozapine in treatment of patients with first-onset schizophrenia","volume":"9","author":"Wang","year":"2004","journal-title":"Chinese Journal of Clinical Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB98|cit98","first-page":"333","article-title":"Cognitive function and p300 potentials in first-episode schizophrenia treated with quetiapine and risperidone","volume":"19","author":"Wang","year":"2005","journal-title":"Chinese Mental Health Journal"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB99|cit99","first-page":"168","article-title":"Comparison of cognitive function and event related potentials in first episode schizophrenic treated with antipsychotic drugs","volume":"15","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychological Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB100|cit100","first-page":"118","article-title":"Clinical study of quetiapine and risperidone in the treatment of schizophrenia","volume":"11","author":"Wang","year":"2005","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"key":"10.1002\/14651858.CD006625.pub2-BIB101|cit101","first-page":"235","article-title":"Analysis of quetiapine in treatment of first-episode schizophrenia","volume":"18","author":"Wang","year":"2005","journal-title":"Sichuai Psychiatry Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB102|cit102","first-page":"271","article-title":"A comparative study between quetiapine and clozapine in the treatment of schizophrenia","volume":"13","author":"Wang","year":"2005","journal-title":"Heath Psychology Journal"},{"issue":"8","key":"10.1002\/14651858.CD006625.pub2-BIB103|cit103","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1038\/sj.npp.1300216","article-title":"Comparison of cognitive performances during a placebo period and an atypical antipsychotic treatment period in schizophrenia: critical examination of confounds","volume":"28","author":"Weickert","year":"2003","journal-title":"Neuropyschopharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB104|cit104","first-page":"40","article-title":"Treatment of 31 cases of schizophrenia with quetiapine","volume":"24","author":"Xiang","year":"2005","journal-title":"Herald of Medicine"},{"key":"10.1002\/14651858.CD006625.pub2-BIB105|cit105","first-page":"227","article-title":"A study of Quetiapine in treatment of schizophrenia","volume":"12","author":"Xu","year":"2002","journal-title":"Journal of Clinical Psychology Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006625.pub2-BIB106|cit106","first-page":"542","article-title":"Effects of domestic quetiapine vs clozapine in treatment of schizophrenia","volume":"7477","author":"Xu","year":"2003","journal-title":"Chinese Journal of New Drugs and Clinical Remedies"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB107|cit107","first-page":"20","article-title":"Comparison of efficacy and safety of seroquel and risperidone in the treatment of schizophrenia","volume":"9","author":"Xu","year":"2005","journal-title":"Journal of Jiangsu Clinical Medicine"},{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB108|cit108","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/00019442-200505000-00006","article-title":"Influence of aging on the improvement of subjective sleep quality by atypical antipsychotic drugs in patients with schizophrenia: comparison of middle-aged and older adults","volume":"13","author":"Yamashita","year":"2005","journal-title":"American Journal of Geriatric Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB109|cit109","first-page":"12","article-title":"Control study on quetiapine and clozapine in treatment of refractory schizophrenia","volume":"16","author":"Yang","year":"2004","journal-title":"Medical Journal of Chinese People Health"},{"issue":"3","key":"10.1002\/14651858.CD006625.pub2-BIB110|cit110","first-page":"159","article-title":"The effect of quetiapine and risperidone on the EEG of first-episode schizophrenic patients","volume":"18","author":"Yang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB111|cit111","first-page":"4","article-title":"Comparison of Quetiapine and Clozapine in treatment of schizophrenia","volume":"25","author":"Yu","year":"2003","journal-title":"Journal of Clinical Psychiatry Medicine"},{"issue":"2B","key":"10.1002\/14651858.CD006625.pub2-BIB112|cit112","first-page":"482","article-title":"A contrast observation of quetiapine and clozapine in affecting electroencephalogram","volume":"12","author":"Yuan","year":"2005","journal-title":"Journal of Practical Medical Techniques"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB113|cit113","first-page":"262","article-title":"A comparative study between quetiapine and risperidone in the treatment of schizophrenia","volume":"11","author":"Zhang","year":"2003","journal-title":"Health Psychology Journal"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB114|cit114","first-page":"86","article-title":"A comparative study of quetiapine and clozapine in the treatment of schizophrenia","volume":"18","author":"Zhang","year":"2005","journal-title":"Shandong Archives of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB115|cit115","first-page":"91","article-title":"A comparative study of social function in schizophrenia patients treated with seroquel (quetiapine) or clozapine","volume":"18","author":"Zhang","year":"2005","journal-title":"Sichuan Mental Health"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB116|cit116","first-page":"290","article-title":"A comparative study of EKG changed by quetiapine and clozapine in the treatment of schizophrenia","volume":"17","author":"Zhang","year":"2005","journal-title":"Medical Journal of Chinese People Health"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB117|cit117","first-page":"260","article-title":"A comparative study of quetiapine combined with clomipramine in treatment of schizophrenia with obsessive-compulsive symptoms","volume":"13","author":"Zhang","year":"2005","journal-title":"Chinese Journal of Health Psychology"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB118|cit118","first-page":"25","article-title":"Control studies of quetiapine and risperidone in the treatment of schizophrenia","volume":"10","author":"Zhao","year":"2004","journal-title":"Journal of Clinical Psychosomatic Diseases"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB119|cit119","first-page":"56, 79-80","article-title":"Control study of quetiapine and risperidone in treatment of schizophrenics","volume":"13","author":"Zhao","year":"2005","journal-title":"Heath Psychology Journal"},{"key":"10.1002\/14651858.CD006625.pub2-BIB120|cit120","first-page":"231","article-title":"A study of quetiapine and clozapine in treatment of schizophrenia","volume":"15","author":"Zhao","year":"2005","journal-title":"Journal of Clinical Psychology Medicine"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB121|cit121","first-page":"30","article-title":"Effect of antipsychotic plus buflomedil hydrochlorde in ameliorating the negative symptoms of patients with schizophrenia","volume":"10","author":"Zhong","year":"2006","journal-title":"Zhongguo Linchuang Kangfu"},{"issue":"6","key":"10.1002\/14651858.CD006625.pub2-BIB122|cit122","first-page":"395","article-title":"A control of treating chronic schizophrenia with seroquel or clozapine","volume":"38","author":"Zhou","year":"2003","journal-title":"Jiangxi Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB123|cit123","first-page":"215","article-title":"A comparative study of quetiapine and clozapine in the treatment of patients with schizophrenia","volume":"15","author":"Zhou","year":"2003","journal-title":"Shanghai Archives of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB124|cit124","unstructured":"Eli Lilly Company Comparison of continuing olanzapine to switching to quetiapine in overweight or obese patients with schizophrenia and schizoaffective disorder Eli Lilly and Company Clinical Trial Registry 2004"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006625.pub2-BIB125|cit125","first-page":"S509","article-title":"A comparative study of quetiapine and risperidone in patients with first-episode psychosis","volume":"15","author":"Gafoor","year":"2005","journal-title":"Journal of the European College of Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB126|cit126","unstructured":"Ratna L A multi-centre, double-blind, randomised study to compare the safety tolerability and efficacy of quetiapine and risperidone in the treatment of schizophrenia in subjects with inadequate symptom control mproved Response In Schizophrenia - IRIS National Research Register 2003"},{"key":"10.1002\/14651858.CD006625.pub2-BIB127|cit127","unstructured":"Reynolds C A six month, rater blind comparison of quetiapine and risperidone in the treatment of tardive dyskinesia in patients with schizophrenia National Research Register 2001"},{"key":"10.1002\/14651858.CD006625.pub2-BIB128|cit128","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecing skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006625.pub2-BIB129|cit129","unstructured":"Andreasen NC Scale for the assessment of positive symptoms (SAPS) The University of Iowa 1984"},{"key":"10.1002\/14651858.CD006625.pub2-BIB130|cit130","first-page":"53","article-title":"Scale for the assessment of negative symptoms (SANS)","volume":"7","author":"Andreasen","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB131|cit131","first-page":"1","article-title":"Practice guidelines for the treatment of patients with schizophrenia","volume-title":"American Journal of Psychiatry","year":"2004"},{"key":"10.1002\/14651858.CD006625.pub2-BIB132|cit132","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0893-133X(97)00112-7","article-title":"Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence","volume":"18","author":"Arnt","year":"1998","journal-title":"Neuropsychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB133|cit133","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB134|cit134","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006625.pub2-BIB135|cit135","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"key":"10.1002\/14651858.CD006625.pub2-BIB136|cit136","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/schbul\/10.3.388","article-title":"The quality of life scale: an instrument for rating the schizophrenic deficit syndrom","volume":"10","author":"Heinrichs","year":"1984","journal-title":"Schizophrenia Bulletin"},{"key":"10.1002\/14651858.CD006625.pub2-BIB137|cit137","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJM199403103301006","article-title":"Schizophrenia","volume":"330","author":"Carpenter","year":"1994","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006625.pub2-BIB138|cit138","first-page":"233","article-title":"The extrapyramidal symptom rating scale","volume":"7","author":"Chouinard","year":"1980","journal-title":"Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD006625.pub2-BIB139|cit139","series-title":"Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28th; Cape Town, South Africa","article-title":"Issues in the selection for meta-analyses of binary data","author":"Deeks","year":"2000"},{"key":"10.1002\/14651858.CD006625.pub2-BIB140|cit140","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD006625.pub2-BIB141|cit141","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD006625.pub2-BIB142|cit142","volume-title":"Diagnostic and statistical manual of mental disorders","year":"1994"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB143|cit143","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001359.pub2","article-title":"Olanzapine for schizophrenia","author":"Duggan","year":"2005","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006625.pub2-BIB144|cit144","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"13","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD006625.pub2-BIB145|cit145","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004578.pub3","article-title":"Aripiprazole for schizophrenia","author":"El-Sayeh","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD006625.pub2-BIB146|cit146","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB147|cit147","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB148|cit148","unstructured":"Gaebel W Falkai P Weinmann S Wobrock T Treatment guidelines for schizophrenia Steinkopf 2006"},{"key":"10.1002\/14651858.CD006625.pub2-BIB149|cit149","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/BF02244924","article-title":"Seroquel: electrophysiological profile of a potential atypical antipsychotic","volume":"112","author":"Goldstein","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB150|cit150","first-page":"95","article-title":"Preclinical tests that predict clozapine-like atypical antipsychotic actions","volume":"10","author":"Goldstein","year":"1995","journal-title":"Critical issues in the treatment of schizophrenia. International Academy of biochemical Drug Research"},{"key":"10.1002\/14651858.CD006625.pub2-BIB151|cit151","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB152|cit152","volume-title":"ECDEU assessment manual for psychopharmacology","author":"Guy","year":"1976"},{"key":"10.1002\/14651858.CD006625.pub2-BIB153|cit153","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","article-title":"Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine","volume":"163","author":"Heres","year":"2006","journal-title":"American Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB154|cit154","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006625.pub2-BIB155|cit155","doi-asserted-by":"crossref","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008] The Cochrane Collaboration, 2008 Available from www.cochrane-handbook.org","DOI":"10.1002\/9780470712184"},{"key":"10.1002\/14651858.CD006625.pub2-BIB156|cit156","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of the effect on quality of life","volume":"63","author":"Jones","year":"2006","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB157|cit157","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment of treatment-resistant schizophrenia: a double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Archives of General Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB158|cit158","first-page":"585","article-title":"Treatment programme and long term outcome in chronic schizophrenia","volume":"46","author":"Kane","year":"1993","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD006625.pub2-BIB159|cit159","volume-title":"Positive and negative syndrome scale (PANSS) manual","author":"Kay","year":"1986"},{"key":"10.1002\/14651858.CD006625.pub2-BIB160|cit160","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"key":"10.1002\/14651858.CD006625.pub2-BIB161|cit161","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of Brief Psychiatric Rating Scale Scores (BPRSS)","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB162|cit162","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia","volume":"353","author":"Liebermann","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006625.pub2-BIB163|cit163","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales - a major source of bias in randomised controlled trials of treatments for schizophrenia?","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD006625.pub2-BIB164|cit164","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00127-004-0762-4","article-title":"Schizophrenia and employment - a review","volume":"39","author":"Marvaha","year":"2004","journal-title":"Social Psychiatry and Psychiatric Epidemiology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB165|cit165","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/BF02244925","article-title":"Seroquel: behavioral profile of a potential atypical antipsychotic","volume":"112","author":"Migler","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB166|cit166","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1001\/jama.285.15.1987","article-title":"The CONSORT statement: Revised recommendations for improving the quality of reports of parallel group randomized trials","volume":"285","author":"Moher","year":"2001","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD006625.pub2-BIB167|cit167","first-page":"329","article-title":"New assessment of atypical antipsychotics","volume":"71","author":"M\u00f6ller","year":"2000","journal-title":"Nervenarzt"},{"key":"10.1002\/14651858.CD006625.pub2-BIB168|cit168","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The Brief Psychiatric Rating Scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"key":"10.1002\/14651858.CD006625.pub2-BIB169|cit169","volume-title":"Modern Psychometrics","author":"Rust","year":"1989"},{"key":"10.1002\/14651858.CD006625.pub2-BIB170|cit170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02244923","article-title":"Seroquel: biochemical profile of a potential atypical antipsychotic","volume":"112","author":"Saller","year":"1993","journal-title":"Psychopharmacology"},{"key":"10.1002\/14651858.CD006625.pub2-BIB171|cit171","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side-effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatrica Scandinavica Supplementum"},{"issue":"Issue 2","key":"10.1002\/14651858.CD006625.pub2-BIB172|cit172","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000967.pub2","article-title":"Quetiapine for schizophrenia","author":"Srisurapanont","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD006625.pub2-BIB173|cit173","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2008.04.011","article-title":"Schizophrenia, \"Just the Facts\" What we know in 2008. 2. Epidemiology and etiology","volume":"102","author":"Tandon","year":"2008","journal-title":"Schizophrenia research"},{"key":"10.1002\/14651858.CD006625.pub2-BIB174|cit174","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1001\/archpsyc.1978.01770260031002","article-title":"Suicide in schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality","volume":"35","author":"Tsuang","year":"1978","journal-title":"Archives of General Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD006625.pub2-BIB175|cit175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"key":"10.1002\/14651858.CD006625.pub2-BIB176|cit176","volume-title":"The World Health Report 2001 - Mental health: New understanding, new hope","year":"2001"},{"key":"10.1002\/14651858.CD006625.pub2-BIB177|cit177","series-title":"Proceedings of the 15th Cochrane Colloquium; 2007 Oct 23-27; Sao Paulo","article-title":"The Leeds Outcomes Stakeholders Survey (LOSS) Study","author":"Xia","year":"2007"},{"key":"10.1002\/14651858.CD006625.pub2-BIB178|cit178","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1176\/appi.ajp.2008.08030368","article-title":"A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia","volume":"166","author":"Leucht","year":"2009","journal-title":"American Journal of Psychiatry"}],"updated-by":[{"DOI":"10.1002\/14651858.cd006625.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,11,18]],"date-time":"2013-11-18T00:00:00Z","timestamp":1384732800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD006625.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T18:01:58Z","timestamp":1628532118000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD006625.pub2"}},"subtitle":[],"editor":[{"given":"Katja","family":"Komossa","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2010,1,20]]},"references-count":178,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006625.pub2","relation":{},"subject":[],"published":{"date-parts":[[2010,1,20]]}}}